Neumora Therapeutics, Inc. (NASDAQ:NMRA) Receives $16.50 Consensus Target Price from Analysts

Neumora Therapeutics, Inc. (NASDAQ:NMRA) has been assigned an average rating of “Moderate Buy” from the seven ratings firms that are currently covering the stock, MarketBeat.com reports. Two investment analysts have rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average 1 year price target among brokerages that have issued ratings on the stock in the last year is $16.50.

A number of equities analysts have recently commented on NMRA shares. JPMorgan Chase & Co. lowered shares of Neumora Therapeutics from an “overweight” rating to a “neutral” rating and reduced their target price for the stock from $18.00 to $15.00 in a research report on Tuesday, November 5th. Needham & Company LLC restated a “buy” rating and set a $23.00 price objective on shares of Neumora Therapeutics in a report on Thursday, January 2nd. William Blair reiterated an “outperform” rating on shares of Neumora Therapeutics in a report on Wednesday, January 15th. HC Wainwright restated a “buy” rating and set a $30.00 price target on shares of Neumora Therapeutics in a research note on Friday, February 14th. Finally, Bank of America lowered their price objective on shares of Neumora Therapeutics from $22.00 to $7.00 and set a “buy” rating for the company in a research note on Monday, January 6th.

Neumora Therapeutics Trading Up 5.3 %

NASDAQ NMRA opened at $1.80 on Friday. The stock has a market cap of $290.81 million, a PE ratio of -0.96 and a beta of 2.50. Neumora Therapeutics has a 12 month low of $1.60 and a 12 month high of $21.00. The company’s 50-day moving average price is $4.30 and its 200-day moving average price is $9.29.

Institutional Investors Weigh In On Neumora Therapeutics

A number of institutional investors have recently added to or reduced their stakes in the stock. Capital International Investors grew its position in shares of Neumora Therapeutics by 692.1% in the 4th quarter. Capital International Investors now owns 3,700,359 shares of the company’s stock worth $39,224,000 after buying an additional 3,233,179 shares during the last quarter. State Street Corp boosted its stake in Neumora Therapeutics by 65.3% in the third quarter. State Street Corp now owns 1,790,707 shares of the company’s stock valued at $23,655,000 after acquiring an additional 707,409 shares in the last quarter. Geode Capital Management LLC grew its holdings in Neumora Therapeutics by 54.0% in the third quarter. Geode Capital Management LLC now owns 1,979,847 shares of the company’s stock worth $26,159,000 after purchasing an additional 694,385 shares during the last quarter. Stempoint Capital LP acquired a new position in shares of Neumora Therapeutics during the fourth quarter worth $4,538,000. Finally, Charles Schwab Investment Management Inc. lifted its holdings in shares of Neumora Therapeutics by 139.7% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 698,255 shares of the company’s stock valued at $9,224,000 after purchasing an additional 406,891 shares during the last quarter. Institutional investors own 47.65% of the company’s stock.

About Neumora Therapeutics

Neumora Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.